A new drug candidate has shown impressive results in a mid-stage clinical trial for drug-resistant epilepsy, raising hopes ...

SK Biopharmaceutical’s Xcopri (cenobamate) met the bar in a phase 3 trial that could support the company’s ambitions of ...

Find out why early recognition of treatment challenges is vital in focal epilepsy management and who is most at risk. Keep reading.

Shares of Rapport Therapeutics popped Monday morning after Phase IIa data for RAP-219 exceeded analyst and Wall Street ...

A phase 2a trial of Rapport Therapeutics’ focal onset seizure drug candidate has hit its primary endpoint, sending shares in ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Among those deemed “treatment sensitive,” 69.4% ...

Rapport Therapeutics stock catapulted Monday after its drug reduced seizures in patients with a hard-to-treat form of ...

Shares of Rapport Therapeutics RAPP surged 61.6% in a week after the company reported positive top-line data from a mid-stage ...

Please provide your email address to receive an email when new articles are posted on . Researchers examined data of 40 adults with focal epilepsy. Patients from disadvantaged neighbhorhoods tended to ...

University of California San Diego is conducting new, Phase 2/3 national epilepsy clinical research trials, called Rise, to study BHV-7000, a novel investigational therapy, in focal epilepsy.

Early detection of focal epilepsy may reduce the amount of motor vehicle accidents caused by seizures while driving. The prevalence of seizures while driving (SzWD) prior to diagnosis in people with ...